Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options

Pastena, Paola; Frye, Jesse T.; Ho, Carson; Goldschmidt, Marc E.; Kalogeropoulos, Andreas P.

doi:10.1007/s10741-023-10377-4

Cited by 12 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ischemic cardiomyopathy (ICM), a prevalent clinical entity, significantly contributes to cardiovascular mortality, particularly as the aging population witnesses a rising incidence, heightening public health concerns [ 1 ]. This condition accounts for 20% of coronary artery disease, with a 5-year mortality rate ranging from 50% to 84%, placing it at the forefront of global cardiovascular research.…”

Section: Introductionmentioning

confidence: 99%

“…This condition accounts for 20% of coronary artery disease, with a 5-year mortality rate ranging from 50% to 84%, placing it at the forefront of global cardiovascular research. A comprehensive understanding of ischemic heart disease’s pathophysiology is pivotal for effective prevention and therapy [ 1 ]. Gal-3, a biomarker in heart failure diagnosis and proposed for general population prediction, has limited research in ischemic heart disease [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of galectin-3, fractalkine, IL-6, miR-21 and cardiac troponin I in human ischemic cardiomyopathy

Wang,

Li,

Zheng

et al. 2024

Aging

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic value of galectin-3, fractalkine, IL-6, miR-21 and cardiac troponin I in human ischemic cardiomyopathy

Wang,

Li,

Zheng

et al. 2024

Aging

View full text Add to dashboard Cite

“…IHD, also known as coronary artery disease (CAD), presents itself as myocardial infarction (MI) and ischemic cardiomyopathy (ICM) in clinical applications. MI is the death of myocardial cells resulting from prolonged ischemia (Thygesen et al 2007), and ICM is commonly referred to as left ventricular (LV) dysfunction accompanied by significant CAD (Del Buono et al 2022;Pastena et al 2024).…”

Section: Introductionmentioning

confidence: 99%

Personalized evaluation of the passive myocardium in ischemic cardiomyopathy via computational modeling using Bayesian optimization

Torbati,

Daneshmehr,

Pouraliakbar

et al. 2024

Biomech Model Mechanobiol

View full text Add to dashboard Cite

Biomechanics-based patient-specific modeling is a promising approach that has proved invaluable for its clinical potential to assess the adversities caused by ischemic heart disease (IHD). In the present study, we propose a framework to find the passive material properties of the myocardium and the unloaded shape of cardiac ventricles simultaneously in patients diagnosed with ischemic cardiomyopathy (ICM). This was achieved by minimizing the difference between the simulated and target end-diastolic pressure-volume relationships (EDPVRs) using black-box Bayesian optimization, based on the finite element analysis (FEA).End-diastolic (ED) biventricular geometry and the location of the ischemia were determined from cardiac magnetic resonance (CMR) imaging. We employed our pipeline to model the cardiac ventricles of three patients aged between 57 and 66 years, with and without the inclusion of valves. An excellent agreement between the simulated and target EDPVRs has been reached. Our results revealed that the incorporation of valvular springs typically leads to lower hyperelastic parameters for both healthy and ischemic myocardium, as well as a higher fiber Green strain in the viable regions compared to models without valvular stiffness. Furthermore, the addition of valve-related effects did not result in significant changes in myofiber stress after optimization. We concluded that more accurate results could be obtained when cardiac valves were considered in modeling ventricles. The present novel and practical methodology paves the way for developing digital twins of ischemic cardiac ventricles, providing a non-invasive assessment for designing optimal personalized therapies in precision medicine.

show abstract

Cardiomyopathy: pathogenesis and therapeutic interventions

Huang,

Li,

et al. 2024

MedComm

View full text Add to dashboard Cite

Cardiomyopathy is a group of disease characterized by structural and functional damage to the myocardium. The etiologies of cardiomyopathies are diverse, spanning from genetic mutations impacting fundamental myocardial functions to systemic disorders that result in widespread cardiac damage. Many specific gene mutations cause primary cardiomyopathy. Environmental factors and metabolic disorders may also lead to the occurrence of cardiomyopathy. This review provides an in‐depth analysis of the current understanding of the pathogenesis of various cardiomyopathies, highlighting the molecular and cellular mechanisms that contribute to their development and progression. The current therapeutic interventions for cardiomyopathies range from pharmacological interventions to mechanical support and heart transplantation. Gene therapy and cell therapy, propelled by ongoing advancements in overarching strategies and methodologies, has also emerged as a pivotal clinical intervention for a variety of diseases. The increasing number of causal gene of cardiomyopathies have been identified in recent studies. Therefore, gene therapy targeting causal genes holds promise in offering therapeutic advantages to individuals diagnosed with cardiomyopathies. Acting as a more precise approach to gene therapy, they are gradually emerging as a substitute for traditional gene therapy. This article reviews pathogenesis and therapeutic interventions for different cardiomyopathies.

show abstract

Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options

Cited by 12 publications

References 79 publications

Diagnostic value of galectin-3, fractalkine, IL-6, miR-21 and cardiac troponin I in human ischemic cardiomyopathy

Diagnostic value of galectin-3, fractalkine, IL-6, miR-21 and cardiac troponin I in human ischemic cardiomyopathy

Personalized evaluation of the passive myocardium in ischemic cardiomyopathy via computational modeling using Bayesian optimization

Cardiomyopathy: pathogenesis and therapeutic interventions

Contact Info

Product

Resources

About